Facilitating Access to Approved Medication
Get Access To Cobimetinib Tablets 20 mg

Cobimetinib Tablets
- Innovator Brand Name – N/A
- Generic Brand Available – Cotellic
- API – Cobimetinib
- Packaging – 63 Tablets
- Strength – 20 mg
What is Cobimetinib Tablets used for?
Cobimetinib tablets are used in combination with vemurafenib to treat melanoma (skin cancer) that has spread or that cannot be removed by surgery.
Disclaimer
All Trademarks and Brands that appear on website belong to their respective owners and Ikris Pharma Network does not lay and claim on them we only provide Information. We are NOT ONLINE store and We do not sell Narcotics and Sedatives. Iron Sucrose is a pharmaceutical drug that legally requires a medical prescription to be dispensed. Following Information meant for Wholesalers, Suppliers, Exporters, Doctors, Comparator Supplies, Hospitals, Generic, Brand, Corporate Sourcing, reseller, and Pharmacies.
Get Access To Cobimetinib Tablets 20 mg
Shreyaansh Lifesciences, Jaipur. India
Shreyaansh Lifesciences is registered in Jaipur, India. Registration Number : 08AEEFS9350K1ZI under GST Act.
Branch Offices in India : Jaipur | New Delhi
SF-72-73 2ND FLOOR, Jaipur Electronic Market, Ridhi Sidhi Choraha, Jaipur, Rajasthan, 302018.
+91 99292 77766
Facts of Medicines
INDICATIONS AND USAGE
COTELLIC is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib. Limitation of Use: COTELLIC is not indicated for treatment of patients with wild-type BRAF melanoma.
DOSAGE AND ADMINISTRATION
Confirm the presence of BRAF V600E or V600K mutation in tumor specimens prior to initiation of COTELLIC. The recommended dose is 60 mg orally once daily for the first 21 days of each 28-day cycle until disease progression or unacceptable toxicity. Take COTELLIC with or without food.
ADVERSE REACTIONS
Most common adverse reactions for COTELLIC (≥20%) are diarrhea, photosensitivity reaction, nausea, pyrexia, and vomiting. The most common
(≥5%) Grade 3-4 laboratory abnormalities are increased GGT, increased CPK, hypophosphatemia, increased ALT, lymphopen.
WARNINGS AND PRECAUTIONS
- New primary malignancies, cutaneous and non-cutaneous: Monitor patients for new malignancies prior to initiation of therapy, while on therapy, and for up to 6 months following the last dose of COTELLIC.
- Hemorrhage: Major hemorrhagic events can occur with COTELLIC. Monitor for signs and symptoms of bleeding.
- Cardiomyopathy: The risk of cardiomyopathy is increased in patients receiving COTELLIC with vemurafenib compared with vemurafenib as a
single agent. The safety of COTELLIC has not been established in patients with decreased left ventricular ejection fraction (LVEF). Evaluate LVEF
before treatment, after one month of treatment, then every 3 months thereafter during treatment with COTELLIC.
FAQs – Medicine Questions
What is cobimetinib used for?
Is Cobimetinib FDA approved?
What is vemurafenib and Cobimetinib?
Where can I buy Cobimetinib Tablets?
You can buy Cobimetinib Tablets from any authorized whole-seller after getting a prescription from a qualified doctor. It is always better to check the credential of the whole-seller/supplier/exporter before buying the product.
The buyer should check the existing law in their home country before importing the product.
What is the procedure to buy Cobimetinib Tablets?
Patients can simply fill the order form or can send mail at info@treatmentoptions4u.com. Patients can also send WhatsApp messages to +91 99292 77766 / 98738 10020 We will reply ASAP with the details of the Cobimetinib Tablets price as well as procurement procedure.
Note:- The order will be confirmed only after the receipt of the Valid prescription of the Clinician.
What is Cotellic used for?
COTELLIC is a prescription medicine that is used with the medicine ZELBORAF, to treat a type of skin cancer called melanoma that has spread to other parts of the body or cannot be removed by surgery, and that has a certain type of abnormal “BRAF” gene.
NEWS / UPDATES